Glycogen-synthase kinase-3β is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment

Experimental Gerontology

Volumn 44, Issue 6-7, 2009, Pages 370-371

  Marksteiner, Josef ^a   Humpel, Christian ^b  

^a Department of Psychiatry and Psychotherapy ^*  (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer; GSK 3; Monocytes; Tau protein

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; BLOOD; COGNITIVE DEFECT; FEMALE; GENETICS; MALE; METABOLISM; MONOCYTE; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MONOCYTES; RISK FACTORS; TAU PROTEINS;

EID: 67349183939     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2009.02.007     Document Type: Note

References (14)

1. Bhat R.V., and Budd S.L. GSK3beta signalling: casting a wide net in Alzheimer's disease. Neurosignals 11 5 (2002) 251-261
2. Castri P., Iacovelli L., De Blasi A., Giubilei F., Moretti A., Capone F.T., Nicoletti F., and Orzi F. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur. J. Neurosci. 26 9 (2007) 2469-2472
3. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8 3 (2002) 126-132
4. Forde J.E., and Dale T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 64 15 (2007) 1930-1944
5. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., and Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147 1 (1992) 58-62
6. Hooper C., Killick R., and Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104 (2008) 1433-1439
7. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R.C., Hamilton G., Powell J., Anderton B., and Lovestone S. Glycogen synthase kinase-3 is increased in whote cells early in Alzheimer's disease. Neurosci. Lett. 373 (2005) 1-4
8. Kvetnoy I.M., Hernandez-Yago J., Kvetnaia T.V., Khavinson V.K., Malinin V.V., Yarilin A.A., Sharova N.I., Blesa J.R., Anisimov V.N., Lenskaia L.V., Sluchevskaia S.F., Chekalina S.I., Tokarev O.Y., and Yuzhakov V.V. Tau-protein expression in human blood lymphocytes: a promising marker and suitable sample for life-time diagnosis of Alzheimer's disease. Neuro Endocrinol. Lett. 21 4 (2000) 313-318
9. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., and Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314 3 (1992) 315-321
10. Manoukian A.S., and Woodgett J.R. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 84 (2002) 203-229
11. Marksteiner, J., Kemmler, G., Weiss, E.M., Knaus, G., Ullrich, C., Mechteriakov, S., Oberbauer, H., Auffinger, S., Hinterhölzl, J., Hinterhuber, H., Humpel. C., in press. Seven out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimers disease. Neurobiol. Aging.
12. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., and Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58 9 (1999) 1010-1019
13. Phiel C.J., Wilson C.A., Lee V.M.-Y., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435-439
14. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., and Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92 3 (1996) 232-241